Abstract:Cardiovascular disease is the leading cause of mortality in many economically developed nations, and its incidence is increasing at a rapid rate in emerging economies. Diet and lifestyle issues are closely associated with a myriad of cardiovascular disease risk factors including abnormal plasma lipids, hypertension, insulin resistance, diabetes and obesity, suggesting that diet-based approaches may be of benefit. Omega-3 longchain-polyunsaturated fatty acids (ω3 LC-PUFA) are increasingly being used in the prevention and management of several cardiovascular risk factors. Both the ω3 and ω6 PUFA families are considered essential, as the human body is itself unable to synthesize them. The conversion of the two precursor fatty acids - linoleic acid (18:2ω6) and α-linoleic acid (α18:3ω3) - of these two pathways to longer (≥C(20)) PUFA is inefficient. Although there is an abundance of ω6 PUFA in the food supply; in many populations the relative intake of ω3 LC-PUFA is low with health authorities advocating increased consumption. Fish oil, rich in eicosapentaenoic (EPA, 20:5ω3) and docosahexaenoic (DHA, 22:6ω3) acids, has been found to cause a modest reduction in blood pressure at a dose level of >3g/d both in untreated and treated hypertensives. Whilst a multitude of mechanisms may contribute to the blood pressure lowering action of ω3 LC-PUFA, improved vascular endothelial cell function appears to play a central role. Recent studies which evaluated the potential benefits of fish oil in type-2 diabetes have helped to alleviate concerns raised in some previous studies which used relatively large dose (5-8 g/d) and reported a worsening of glycemic control. Several meta-analyses have confirmed that the most consistent action of ω3 LC-PUFA in insulin resistance and type-2 diabetes is the reduction in triglycerides. In some studies, fish oil has been found to cause a small rise in LDL-cholesterol, but a change in the LDL particle size, from the smaller more atherogenic form to the larger, less damaging particle size, have also been noted. ω3 LC-PUFA are effective modulators of the inflammation that accompanies several cardio-metabolic abnormalities. Taking into consideration the pleiotropic nature of their actions, it can be concluded that dietary supplementation with ω3 LC-PUFA will lead to improvements in cardio-metabolic health parameters. These fatty acids pose only minor side effects and more importantly, do not interact adversely with the common drug therapies used in the management and treatment of hypertension, dyslipidemia, type-2 diabetes, and obesity/metabolic syndrome, but in some instances work synergistically, thereby providing additional cardiovascular benefits.

Effects of Fish Oil-Derived Fatty Acids on Suboptimal Cardiovascular Health: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Effects of n-3 fatty acid supplements on cardiometabolic profiles in hypertensive patients with abdominal obesity in Inner Mongolia: a randomized controlled trial.

Effects of N-3 Fatty Acid Supplements on Glycemic Traits in Chinese Type 2 Diabetic Patients: A Double-Blind Randomized Controlled Trial.

Abstract 4142898: Marine N-3 Fatty Acids Improve Carotid Atherosclerosis in Diabetic Patients

Change Of Plasma Metabolites In Response To Omega-3 Fatty Acids In Chinese Patients With Type 2 Diabetes: A Double-Blinded Randomized Controlled Trial

Effects of Dietary Supplementation of Fish Oil Plus Vitamin D3 on Gut Microbiota and Fecal Metabolites, and Their Correlation with Nonalcoholic Fatty Liver Disease Risk Factors: a Randomized Controlled Trial

The effects of fish oil plus vitamin D 3 intervention on non-alcoholic fatty liver disease: a randomized controlled trial

Effects of Different N-6/N-3 Polyunsaturated Fatty Acids Ratios on Lipid Metabolism in Patients with Hyperlipidemia: a Randomized Controlled Clinical Trial.

Effect of Plant-Derived n-3 Polyunsaturated Fatty Acids on Blood Lipids and Gut Microbiota: A Double-Blind Randomized Controlled Trial

Serum metabolomics profiles in response to n-3 fatty acids in Chinese patients with type 2 diabetes: a double-blind randomised controlled trial

Effect of Vitamin B_12 and N-3 Polyunsaturated Fatty Acids on Plasma Homocysteine, Ferritin, C-Reaction Protein, and Other Cardiovascular Risk Factors: a Randomized Controlled Trial

Changes of urine metabolites in response to n-3 fatty acid supplements and their correlation with metabolic risk factors in patients with type 2 diabetes.

Role of ω3 long-chain polyunsaturated fatty acids in reducing cardio-metabolic risk factors

[Effects of Ω-3 Polyunsaturated Fatty Acids from Different Sources on Glucolipid Metabolism in Type 2 Diabetic Patients with Dyslipidemia].

Fatty Acid and Non-Alcoholic Fatty Liver Disease: Meta-analyses of Case-Control and Randomized Controlled Trials.

Lowering Effects of N-3 Fatty Acid Supplements on Blood Pressure by Reducing Plasma Angiotensin II in Inner Mongolia Hypertensive Patients: A Double-Blind Randomized Controlled Trial.

Effects of Marine-Derived and Plant-Derived Omega-3 Polyunsaturated Fatty Acids on Erythrocyte Fatty Acid Composition in Type 2 Diabetic Patients.

Effect of N-3 PUFA on Left Ventricular Remodelling in Chronic Heart Failure: a Systematic Review and Meta-Analysis

Effect of ω-3PUFA on Lipids and Expression of Inflammation in Type 2 Diabetes Mellitus

Effect of Deep Sea Fish Oil on Intervention of Cardiovascular Sub-Healthy Checkups